• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
EGFR L747P mutation in one lung adenocarcinoma patient responded to afatinib treatment: a case report.一名肺腺癌患者的表皮生长因子受体（EGFR）L747P突变对阿法替尼治疗有反应：病例报告
J Thorac Dis. 2018 Dec;10(12):E802-E805. doi: 10.21037/jtd.2018.12.26.
2
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations.阿法替尼治疗罕见 EGFR p.L747P 和 p.L747S 突变型肺腺癌有效。
Lung Cancer. 2019 Jul;133:103-109. doi: 10.1016/j.lungcan.2019.05.019. Epub 2019 May 17.
3
Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases.病例报告：达可替尼对具有罕见表皮生长因子受体（EGFR）L747P突变及脑转移的肺腺癌有效。
Front Oncol. 2022 Aug 9;12:863771. doi: 10.3389/fonc.2022.863771. eCollection 2022.
4
EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.表皮生长因子受体（EGFR）突变L747P导致一名中国肺腺癌患者对吉非替尼产生耐药，并加速了肝转移。
Int J Clin Exp Pathol. 2015 Jul 1;8(7):8603-6. eCollection 2015.
5
Exon 19 L747P mutation presented as a primary resistance to EGFR-TKI: a case report.外显子19 L747P突变表现为对表皮生长因子受体酪氨酸激酶抑制剂的原发性耐药：一例报告
J Thorac Dis. 2016 Jul;8(7):E542-6. doi: 10.21037/jtd.2016.05.95.
6
Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.比较阿法替尼与吉非替尼或厄洛替尼对携带非经典表皮生长因子受体突变的晚期肺腺癌患者的疗效。
Lung Cancer. 2017 Aug;110:56-62. doi: 10.1016/j.lungcan.2017.06.007. Epub 2017 Jun 13.
7
Afatinib for an EGFR exon 20 insertion mutation: A case report of progressive stage IV metastatic lung adenocarcinoma with 54 months' survival.阿法替尼用于表皮生长因子受体第20外显子插入突变：1例IV期转移性肺腺癌进展期患者生存54个月的病例报告
Asia Pac J Clin Oncol. 2018 Mar;14 Suppl 1:7-9. doi: 10.1111/ajco.12853.
8
EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib.表皮生长因子受体（EGFR）第18外显子E709_T710缺失并插入D突变的IV期肺腺癌，对阿法替尼有反应。
Lung Cancer. 2017 Jun;108:45-47. doi: 10.1016/j.lungcan.2017.02.023. Epub 2017 Mar 1.
9
Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation.在携带表皮生长因子受体（EGFR）突变的肺腺癌中发现的不同的阿法替尼耐药机制。
Mol Cancer Res. 2017 Jul;15(7):915-928. doi: 10.1158/1541-7786.MCR-16-0482. Epub 2017 Mar 13.
10
Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.不可逆性表皮生长因子受体（ErbB）家族阻滞剂阿法替尼在按人口统计学和基因分型定义的肺腺癌中的II期研究
Lung Cancer. 2015 Apr;88(1):63-9. doi: 10.1016/j.lungcan.2015.01.013. Epub 2015 Jan 23.

引用本文的文献

1
Case of a rare EGFR mutation L identified using the lung cancer compact Panel™ leading to successful Afatinib treatment.使用肺癌紧凑型检测板™鉴定出罕见的表皮生长因子受体（EGFR）L突变病例，阿法替尼治疗成功。
Respir Med Case Rep. 2025 Jul 5;57:102255. doi: 10.1016/j.rmcr.2025.102255. eCollection 2025.
2
EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast.表皮生长因子受体酪氨酸激酶抑制剂治疗罕见表皮生长因子受体突变的转移性非小细胞肺癌：播客。
Target Oncol. 2023 Nov;18(6):807-817. doi: 10.1007/s11523-023-00994-2. Epub 2023 Oct 4.
3
Performance of Ultra-Rapid Idylla™ EGFR Mutation Test in Non-Small-Cell Lung Cancer and Its Potential at Clinical Molecular Screening.超快速Idylla™表皮生长因子受体（EGFR）突变检测在非小细胞肺癌中的性能及其在临床分子筛查中的潜力
Cancers (Basel). 2023 May 7;15(9):2648. doi: 10.3390/cancers15092648.
4
Nuclear export signal mutation of epidermal growth factor receptor enhances malignant phenotypes of cancer cells.表皮生长因子受体的核输出信号突变增强癌细胞的恶性表型。
Am J Cancer Res. 2023 Apr 15;13(4):1209-1239. eCollection 2023.
5
Structure-Guided Strategies of Targeted Therapies for Patients with -Mutant Non-Small Cell Lung Cancer.基于结构的 - 突变型非小细胞肺癌靶向治疗策略。
Biomolecules. 2023 Jan 20;13(2):210. doi: 10.3390/biom13020210.
6
Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases.病例报告：达可替尼对具有罕见表皮生长因子受体（EGFR）L747P突变及脑转移的肺腺癌有效。
Front Oncol. 2022 Aug 9;12:863771. doi: 10.3389/fonc.2022.863771. eCollection 2022.
7
Systemic and Intracranial Efficacy of Osimertinib in L747P-Mutant NSCLC: Case Report.奥希替尼治疗L747P突变型非小细胞肺癌的全身及颅内疗效：病例报告
JTO Clin Res Rep. 2022 Feb 15;3(3):100291. doi: 10.1016/j.jtocrr.2022.100291. eCollection 2022 Mar.
8
The Lifted Veil of Uncommon EGFR Mutation p.L747P in Non-Small Cell Lung Cancer: Molecular Feature and Targeting Sensitivity to Tyrosine Kinase Inhibitors.非小细胞肺癌中罕见表皮生长因子受体（EGFR）p.L747P突变的面纱揭开：分子特征及对酪氨酸激酶抑制剂的靶向敏感性
Front Oncol. 2022 Feb 11;12:843299. doi: 10.3389/fonc.2022.843299. eCollection 2022.
9
A Rare Presentation of a Non-Asian Female With Metastatic Non-small-cell Lung Cancer Harboring L747P Mutation With Clinical Response to Multi-targeted Epigenetic and Inhibition.非亚裔女性转移性非小细胞肺癌患者罕见病例报告，携带 L747P 突变，对多靶点表观遗传和抑制有临床反应。
Anticancer Res. 2022 Jan;42(1):441-447. doi: 10.21873/anticanres.15502.
10
Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review.表皮生长因子受体表达与非小细胞肺癌靶向治疗耐药模式：综述。
Cells. 2021 May 14;10(5):1206. doi: 10.3390/cells10051206.

本文引用的文献

1
Non-small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report.携罕见 EGFR L747P 突变的非小细胞肺癌对吉非替尼和奥希替尼（AZD9291）均表现出内在耐药性：一例报告。
Thorac Cancer. 2018 Jun;9(6):745-749. doi: 10.1111/1759-7714.12637. Epub 2018 Apr 19.
2
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials.剂量调整对阿法替尼治疗表皮生长因子受体突变阳性肺腺癌的安全性和疗效的影响：随机 LUX-Lung 3 和 6 试验的事后分析。
Ann Oncol. 2016 Nov;27(11):2103-2110. doi: 10.1093/annonc/mdw322. Epub 2016 Sep 6.
3
Exon 19 L747P mutation presented as a primary resistance to EGFR-TKI: a case report.外显子19 L747P突变表现为对表皮生长因子受体酪氨酸激酶抑制剂的原发性耐药：一例报告
J Thorac Dis. 2016 Jul;8(7):E542-6. doi: 10.21037/jtd.2016.05.95.
4
EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.表皮生长因子受体（EGFR）突变L747P导致一名中国肺腺癌患者对吉非替尼产生耐药，并加速了肝转移。
Int J Clin Exp Pathol. 2015 Jul 1;8(7):8603-6. eCollection 2015.
5
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.阿法替尼治疗携带非典型 EGFR 突变的晚期非小细胞肺癌患者的临床活性：LUX-Lung 2、LUX-Lung 3 和 LUX-Lung 6 的联合事后分析。
Lancet Oncol. 2015 Jul;16(7):830-8. doi: 10.1016/S1470-2045(15)00026-1. Epub 2015 Jun 4.
6
A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).一项针对亚洲晚期非小细胞肺癌腺癌组织学患者中表皮生长因子受体突变的前瞻性分子流行病学研究（PIONEER）。
J Thorac Oncol. 2014 Feb;9(2):154-62. doi: 10.1097/JTO.0000000000000033.
7
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.基于理性和生物学原理的 EGFR 突变型非小细胞肺癌治疗。
Nat Rev Cancer. 2010 Nov;10(11):760-74. doi: 10.1038/nrc2947. Epub 2010 Oct 22.

EGFR L747P mutation in one lung adenocarcinoma patient responded to afatinib treatment: a case report.

作者信息

Zhou Tong, Zhou Xiaoyue, Li Peng, Qi Chuang, Ling Yang

机构信息

Department of Medical Oncology, Changzhou Cancer Hospital of Soochow University, Changzhou 213032, China.

The Medical Department, 3D Medicines Inc., Shanghai 201100, China.

出版信息

J Thorac Dis. 2018 Dec;10(12):E802-E805. doi: 10.21037/jtd.2018.12.26.

DOI:10.21037/jtd.2018.12.26
PMID:30746257
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6344738/
Abstract
摘要